Internal restructuring
Vlaams Gewest;
Location of affected unit(s)
Vilvoorde and Puurs
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

30 - 100 jobs
Number of planned job losses
Job loss
Announcement Date
28 July 2022
Employment effect (start)
1 July 2022
Foreseen end date
31 December 2024


As part of a global restructuring announcement, the Swiss multinational pharmaceutical company Novartis has stated it will be dismissing 30 employees in their Belgian branch of the company in Vilvoorde. The site employs 288 workers in Vilvoorde and 2,000 across Belgium. As part of the restructuring in Belgium, Novartis will also reduce its workforce at its site in Puurs, however the exact amount has not yet been stated. 

The dismissals are part of a global effort by the company that was announced in April 2022 to reduce costs and rework the company structure to become 'lighter and more simple'. By the end of 2024, the company aims to reduce their global workforce of 108,000 by approximately 8,000 people. 

The responsible trade union, syndicat libéral, has stated its concern for what is the third restructuring over the past five years. The declaration of intent has started the information and consultation phase with the social partners, within the framework of the Renault Law.

Previous factsheets for Novartis' global restructuring have been recorded in the ERM database (Novartis-2022-WO). In 2022, the corresponding job reductions within Spain have been recorded (Novartis-2022a-ES), as well as the seperate announcement of the regional expansion of 124 employees, also in Spain (Novartis-2022-ES).



Eurofound (2022), Novartis , Internal restructuring in Belgium, factsheet number 107121, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/107121.